Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine for social impairment in adolescents with ASD
NCT01972074Phase 3Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Feb 2015
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of memantine in Autism Spectrum Disorder (ASD), sponsored by Massachusetts General Hospital. Started Feb 2015; status: completed.
02
Drugs
memantine
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT01972074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01972074.